Erschienen in:
01.06.2014 | Research Article
Genetic polymorphisms in XPG could predict clinical outcome of platinum-based chemotherapy for advanced non-small cell lung cancer
verfasst von:
Weicai Hu, Jinbing Pan, Pu Zhao, Guangyu Yang, Shujuan Yang
Erschienen in:
Tumor Biology
|
Ausgabe 6/2014
Einloggen, um Zugang zu erhalten
Abstract
We conducted a prospective study to investigate the role of four single nucleotide polymorphisms (SNPs) of XPG on the clinical outcome of advanced non-small cell lung cancer (NSCLC) treated with platinum-based doublets chemotherapy. In total, 277 patients with histologically confirmed NSCLC were mainly from December 2007 and December 2008. The genotypes of rs2296147T > C, rs1047768C > T, rs873601G > A, and rs17655G > C were determined by polymerase chain reaction-restriction fragment length polymorphism. By univariate analysis, a shorter survival was associated with older age, sex, and higher disease stage. By multivariate Cox regression analysis, patients carrying rs2296147 TT genotype and T allele were prognostic factors of progression-free survival (PFS) and overall survival (OS). Similarly, patients carrying rs873601 GG genotype and G allele were marginally significantly associated with favorable outcome for PFS and OS. We found that individuals carrying both rs2296147 T allele and rs873601 G allele were associated with better PFS and OS. However, rs1047768C > T and rs17655G > C polymorphisms did not influence the PFS and OS of advanced NSCLC. In summary, our study provided statistical evidence that XPG rs2296147T > C and rs873601G > A polymorphisms may be used as surrogate markers toward individualizing NSCLC treatment strategies.